₹8,447 crore in medicine overcharging claims remain outstanding as SC seeks wider price controls
The Supreme Court questioned the Centre on extending a 30% trade margin cap for anti-cancer medicines to other drugs. The court seeks broader price controls amid ₹8,447.4 crore in outstanding overcharging claims, as the National Pharmaceutical Pricing Authority continues to pursue violations. The next hearing is scheduled for October 27, 2026.